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Abstract
Objective: Major Depressive Disorder (MDD) is a debilitating condition with a marked social 
impact. The impact of MDD and Treatment-Resistant Depression (TRD+) within the Brazilian 
health system is largely unknown. The goal of this study was to compare resource utilization and 
costs of care for treatment-resistant MDD relative to non-treatment-resistant depression (TRD-). 
Methods: We retrospectively analyzed the records of 212 patients who had been diagnosed with 
Resource utilization was estimated, and the consumption of medication was annualized. We 
obtained information on medical visits, procedures, hospitalizations, emergency department visits 
and medication use related or not to MDD. Results: The sample consisted of 90 TRD+ and 122 
not from non-psychiatric clinics, compared to TRD- patients. Furthermore, TRD+ patients were 
higher (81.5%) annual costs compared to TRD- patients (R$ 5,520.85; US$ 3,075.34 vs. R$ 3,042.14; 
and should be considered by policy makers when implementing public mental health initiatives.
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Depressão resistente ao tratamento aumenta os custos e utilização de recursos
Resumo
Objetivo:
Métodos: 
Foram analisados retrospectivamente os prontuários de 212 pacientes diagnosticados com TDM 
Resultados: A amostra foi composta 
 
(R$ 5.520,85; US$ 3.075,34 contra R$ 3.042,14, US$ 1.694,60). Estes resultados demonstram o 
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Introduction
Major depressive disorder (MDD) is a chronic condition with 
1 and a 1-year preva-
lence ranging from 7%-10%.1-4
Americans and Europeans have had at least one depressive 
episode in their lifetime.2,3,5 MDD is a highly debilitating con-
dition, imposing a considerable economic burden upon suf-
ferers and upon society.6 The economic burden of depression 
has been estimated in several studies worldwide. In fact, MDD 
is associated with higher costs than diseases such as asthma, 
osteoporosis, arterial hypertension and schizophrenia. The 
treatment-related costs (direct costs) of MDD to the United 
the costs due to the loss of productivity (indirect costs) were 
US$ 31.3 billion.8 In addition, costs increased from US$ 77.4 
US dollars).9 
depression published worldwide indicated direct costs 
ranging from US$ 1,000 to US$ 2,500 per patient/year 
in 2003 inflation-adjusted US dollars; costs associated 
with morbidity ranging from US$ 2,000 to US$ 3,700; 
and finally, costs associated with mortality in the range of 
US$ 200 to US$ 400.10 In 2004, the total annual cost 
of depression in Europe was estimated to be around 
€ 118 billion, or € 253 per capita. Indirect costs were 
estimated at € 76 billion. Accordingly, depression is the 
most costly neuropsychiatric disorder in Europe, account-
11 
of those who had at least two episodes will have subsequent 
recurrences.12 Despite available pharmacological and non-
pharmacological treatments, as many as 30% of patients with 
12,13,14 
Indeed only 20 to 40% of the treated MDD patients achieve 
full remission.15 More conservative estimates report that 10 to 
20% of the patients with MDD become resistant to multiples 
forms of therapy.17,18 Patients with treatment-resistant de-
pression (referred herein as TRD+) have a higher number of 
medical visits, increased rates of hospitalization, and higher 
use of psychotropic medications compared to patients with 
non-treatment resistant MDD (TRD-).12,19,20,21 It is suggested 
that resistance to treatment is the main factor determin-
ing the economic burden of depression, rather than MDD 
severity.22
Epidemiological data on the prevalence of MDD and 
TRD+ are scarce in Brazil, and economic data are almost 
morbidity estimated that the 1-month prevalence of depres-
sive disorders ranged from 1.9% to 10.2% in different Brazilian 
regions.23 A second study found a 1-month prevalence of 4.5%, 
1-year prevalence of 7.1%, and lifetime prevalence of 16.8%.24 
study estimated the resource utilization costs of primary 
-
cluding in Porto Alegre, Brazil.25
Accordingly, the objective of this study was to compare 
the resource utilization and the cost of treatment in TRD+ 
versus TRD- patients in a tertiary hospital. An additional 
objective was to estimate the proportion of patients with 
MDD who are TRD+ and to assess the demographic and clini-
cal characteristics of the TRD+ and non-TRD patients. Such 
studies are critical to properly inform decisions regarding 
the allocation of resources and the formulation of public 
strategies to diagnose and treat mental disorders. 
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Method
Data source and sample
records of patients seen from July 1997 to June 2002 at 
the Psychiatric Institute of the Clinics Hospital, School of 
Medicine, University of Sao Paulo, Brazil. 
MDD according to the ICD-10 (F32.0, F32.1, F32.2, F32.3, F32.8, 
F32.9, F33.0, F33.1, F33.2, F33.3, F33.4, or F33.8, F33.9). To 
be included in this analysis, patients had to be followed for at 
least 6 months in the hospital, as recommended by the World 
26
the study if they had comorbid psychosis and/or if they were 
enrolled in a clinical trial during the study period.
The charts of eligible patients were reviewed, and demo-
graphic data, clinical characteristics, and resource utilization 
age, gender, marital status, occupational status and education 
level. Clinical characteristics included psychiatric and medi-
cal comorbidities and the duration of depression treatment. 
Missing demographic data were supplemented with informa-
tion from the hospital statistics department database. 
by Corey-Lisle et al.19 Accordingly, patients in this study were 
required to have at least one of the following between July 
1997 and June 2002:
1. MDD treated with electroconvulsive therapy (ECT) or 
2. Patients who met both the criteria for the TRD scale and 
a. 
• Augmentation with a mood stabilizer (score of 
1) and/or with an antipsychotic (score of 1); 
scores ranging from 0 to 2.
• 
a 5 year period, relative to the switching pattern 
of all MDD patients in the sample. Patients in the 
bottom quartile were scored as 0, with increas-
ing scores until the top quartile (score of 3). 
• 
5 years relative to those of the whole MDD sam-
ple (by quartiles, scores ranging from 0 to 3). 
b. 
• Three or more drug switches, or at least 2 
switches and 2 antidepressant up-titrations 
across the 5 years of data collection. 
 
MDD patients not meeting the criteria for TRD+ were 
considered non-resistant to treatment (TRD-).
Resource utilization and health care costs
Resource utilization and health care costs were estimated by 
measuring all of the health care products and services used 
as per the hospital medical records. Because patients in 
the sample had varied follow-up times (from 6 months to 5 
years), the amount of resources utilized by each patient was 
divided by their respective follow-up time. For each variable, 
we calculated the medium monthly consumption/use, which 
was then annualized. We obtained data on hospitalizations, 
emergency department visits, outpatient costs for medical 
visits and procedures in the psychiatric units as well as in 
other clinics of the hospital, and the costs of all prescribed 
medication (regardless of whether they were provided by 
the public healthcare system or purchased by patients), 
and therapeutic procedures. Costs were calculated in 
Brazilian Reais (R$) and US Dollars (US$) as of March 2010. 
We used the market value for each resource. Market 
value was used instead of the public health system database 
with respect to the true costs of procedures. 
The cost of medical visits, procedures and laboratory 
or imaging tests were estimated by the Brazilian Medical 
rated as R$ 0.29. When procedures were not found in this 
list, we estimated the costs using the list of the School of 
Medicine Foundation from 2010 or the 2003 values corrected 
For medications, costs were calculated using the Brazilian 
Pharmaceutical Guide (March 2010) or the 2003 values cor-
Dental procedures were estimated using the Brazilian 
Dentistry Association list of procedures. Because nurse visits 
were not listed in the AMB list of procedures, they were val-
ued as a proportion of the cost of a medical visit considering 
the hourly wage rates paid by the São Paulo State Secretary of 
activities not reimbursed by health plans were not included in 
the calculations. Disposable materials were also not included 
in our calculation, as medical records do not list them.
Sample size calculation and statistical analyses
Because one of our aims was to compare groups of TRD+ and 
TRD- MDD, we estimated the minimum sample size for TRD+ 
as 36 patients to detect cost differences of 0.5 standard de-
and a power of 90% were considered. The most conservative 
estimate for TRD proportion (15%) was used17 to calculate 
the total sample size of 240 patients.
and treated for at least 6 months. Patients were selected by 
systematic sampling of medical charts with a random starting 
sampling interval = 4, generating 217 potential participants. 
Because our preliminary chart review indicated that a large 
proportion of subjects did not meet the eligibility criteria, 
we repeated the above described procedure. A total of 559 
patients were selected, and 212 were considered eligible.
We used summary tables and descriptive statistics to 
describe demographic and clinical features. Groups were 
compared using the Chi-square test (proportions) for 
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categorical variables, the parametric Student t-test for nor-
mally distributed continuous variables or the non-parametric 
Mann-Whitney test for non-normally distributed continuous 
Smirnov test, and the homogeneity of variance was tested 
with Levene's test.
This study was approved by the Ethics Committees of 
the Clinics Hospital and the Faculdade de Saúde Pública - 
Universidade de São Paulo. All forms and databases were 
by their initials and a sequential number to protect their 
Results
Sample characteristics
met the criteria for TRD-. Table 1 summarizes the demo-
graphics and clinical characteristics per patient group. TRD+ 
gender (p = 0.42), age (p = 0.14), race (p = 0.08), education 
(p = 0.94), marital status (p = 0.68) and employment 
older than 40 (79.2%), with at least some high school educa-
tion (58.5%), married (50.5%), and working at the time of 
the study (42.0%). 
The mean treatment time for TRD+ patients was 6 
TRD- patients (4 years, p < 0.001). Psychiatric comorbidity 
depression was the only psychiatric diagnosis in nearly 70% 
of the patients, regardless of MDD status. The most frequent 
non-psychiatric comorbidities were hypertension (15.1%), 
diabetes (9.4%) and hypothyroidism (7.6%), with no differ-
ences between TRD+ and TRD- patients.
Resource utilization
Table 2 lists the resource utilization by patients with 
TRD+ and TRD-. In the psychiatric clinic, the mean 
number of annual psychiatric outpatient visits was not 
B.A. Lepine et al.
Table 1 Demographic and clinical characteristics
TRD+
(N = 90)
TRD- 
(N = 122) 
p-value
Demographics 
 Age, Mean (SE) 53.8 (1.52) 52.8 (1.48) 0.14
 % Women 76.7 81.1 0.42
 % Working 40.0 43.5 0.83
 % Married 52.2 46.7 0.68
Clinical Characteristics 
Treatment duration (years), Mean (SE) 6.0 (0.43) 4.0 (0.35) < 0.001
Psychiatric Comorbidities, Mean number/patient (SE) 0.38 (0.07) 0.30 (0.05) 0.57
 Mild mental retardation (F70) 1.1% 1.6%
2.2% 1.6%
2.2% 1.6%
 Persistent mood disorders (F34) 3.3% 0.8%
2.2% 2.5%
 Eating disorders (F50) 2.2% 4.9%
5.6% 1.6%
 Disorders due to psychoactive substance use (F10-F19) 8.9% 1.6%
5.6% 6.6%
0.87 (0.11) 0.84 (0.12) 0.67
 Migraine 1.1% 2.5%
 Acute Myocardial Infarction 3.3% 0.8%
 Dyslipidemia 1.1% 3.3%
6.7% 0.0%
 Gastritis and duodenitis 2.2% 4.1%
3.3% 5.7%
 Hypothyroidism 11.1% 7.4% 0.36
 Diabetes 7.8% 9.8% 0.81
 Hypertension 12.2% 17.2% 0.30
TRD: treatment-resistant depression; MDD: major depressive disorder; SE: standard error.
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Table 2 Annual resource utilization 
TRD+ TRD- p-value
Psychiatry, outpatient
Medical Visits
 Mean (SE) 10.56 (0.53) 9.74 (0.44)
 Median 9.50 8.70 0.12
Psychotherapy 
 Mean (SE) 0.05 (0.04) 0.28 (0.20)
 Median 0.00 0.00 **
Diagnostic Tests
 Mean (SE) 8.71(1.03) 7.02 (1.18)
 Median 6.40 0.40 < 0.001
ECT
 Mean (SE) 1.15 (0.47) - -
 Median 0 - -
Medications
 Mean (SE) 1.73 (0.11) 1.49 (0.12) 0.01
 Median
Other Clinics, outpatient
Medical Visits, Mean (SE) 0.30 (0.11) 0.35 (0.11) 0.84
Diagnostic Tests, Mean (SE) 0.70 (0.40) 0.79 (0.26) 0.26
Procedures, Mean - 0.00 -
Medications, Mean (SE) 0.44 (0.07) 0.42 (0.09) 0.01
Emergency Department
Medical Visits, Mean (SE) 0.01 (0.001) 0.02 (0.001) **
Diagnostic Tests - 0.00 -
Procedures - 0.00 -
Medications - 0.00 -
Inpatient Stay
Hospitalizations, Mean (SE) 0.09 (0.02) 0.05 (0.02) 0.009
Inpatient Days, Mean (SE) 3.53 (0.12) 1.72 (0.08) 0.22
Length of Stay* (days), Mean (SE) 37.6 (7.3) 51.4 (24.2) 0.32
Medical Visits, Mean (SE) 2.79 (0.09) 0.77 (0.03) 0.16
0.15 (0.06) 0.24 (0.19) -
10.32 (3.10) 1.35 (0.71) 0.50
Diagnostic Tests, Mean (SE) 1.82 (0.05) 0.66 (0.03) **
Procedures, Mean (SE) 0.52 (0.03) 0.01 (0.001) **
Medications, Mean (SE) 0.52 (0.01) 0.22 (0.01) 0.01
TRD+: Treatment-Resistant Depression; TRD-  
SE: Standard Error.
 
TRD- = 9.74, p = 0.12). However, more laboratory tests 
(median 6.4 vs. 0.4, p < 0.0001) were requested for those 
with TRD+ compared to those with TRD-. Because procedures 
(e.g., electroconvulsive therapy and polysomnography) were 
only performed in the TRD+ group, group comparison was 
not possible. Electroconvulsive therapy was performed in 14 
patients, for a total of 103.81 sessions per year.
Regarding the pharmacological treatment of depres-
sion, over 90% of individuals with TRD- used from one to 
 
In those with TRD+, more than half of the patients used more 
than 10 medications during the same time period (p < 0001).
Regarding resource utilization in specialty clinics other 
among groups with regard to the number of medical visits 
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and laboratory tests. Regarding non-psychiatric medica-
TRD+ group were drugs to treat gastrointestinal tract 
disorders (Table 1). 
The yearly hospitalization rate was higher in the TRD+ 
group compared to TRD- (9% vs. 5%, p = 0.009); the mean 
number of inpatient days per year was also higher in the 
TRD+ group (3.53 vs. 1.72, p = 0.009). Although not statisti-
in a subsample of patients who were admitted to hospital 
was surprisingly shorter in the TRD+ group when compared 
to the TRD- patients (37.6 days vs. 51.4 days, respectively, 
in the number of tests and procedures, or with the medi-
cation utilized during the inpatient stay, when comparing 
both groups. 
Health care costs
Table 3 summarizes the health care costs for TRD+ and 
that of TRD- subjects in all settings but at the emergency 
department. Accordingly, the total individual costs of an-
the TRD- group [R$ 5,520.85 (US$ 3,075.34) vs. R$ 3,042.14 
(US$ 1,694.60, respectively).
vast majority of costs in both groups (60% in TRD+ vs. 72% 
in TRD-), followed by inpatient care (23% in TRD+ vs. 17% in 
treating MDD patients were derived from medication use (67% 
for TRD+ and 72% for TRD-) and inpatient per diem charges 
(15% for TRD+ and 13% for TRD-) (Figure 2).
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Table 3 Mean annual cost of treatment for TRD+ and TRD-, overall and by care category (costs for March 2010)
TRD+ TRD- (R$) MDD (R$)
R$ US$ R$ US$ R$ US$
Psychiatric Clinic
 Medical Visits 245.95 137.00 226.16 125.98 234.56 130.66
3.45 1.92 17.08 9.51 11.29 6.29
0.39 0.22 0.09 0.05 0.22 0.12
 Diagnostic Tests 174.78 97.36 133.44 74.33 150.99 84.11
 Procedures 236.33 131.65 0.00 0.00 100.33 55.89
 Medications 2,637.93 1,469.44 1,798.53 1,001.85 2,154.88 1,200.36
Subtotal 3,298.83 1,837.58 2,175.30 1,211.73 2,652.27 1,477.42
Other Clinics
 Medical Visits 6.96 3.88 7.94 4.42 7.52 4.19
 Diagnostic Tests 12.11 6.75 15.21 8.47 13.89 7.74
 Procedures 0.00 0.00 0.07 0.04 0.04 0.02
 Medications 910.64 507.26 321.99 179.36 571.89 318.57
Subtotal 929.71 517.89 345.21 192.30 593.34 330.51
Emergency Department
 Medical Visits 0.29 0.16 0.41 0,23 0.36 0.20
 Diagnostic Tests 0.00 0.00 0.38 0.21 0.22 0.12
 Procedures 0.00 0.00 0.00 0.00 0.00 0.00
 Medications 0.00 0.00 0.14 0.08 0.08 0.04
Subtotal 0.29 0.16 0.93 0.52 0.66 0.37
Hospitalizations
 Days 849.26 473.07 406.50 226.44 594.47 331.14
 Medical Visits 64.77 36.08 17.91 9.98 37.80 21.06
3.35 1.87 13.51 7.53 7.32 4.08
90.59 50.46 11.85 6.60 45.28 25.22
 Diagnostic Tests 38.01 21.17 12.60 7.02 23.39 13.03
 Procedures 108.14 60.24 2.99 1.67 47.63 26.53
 Medications 137.90 76.82 55.34 30.83 90.39 50.35
Subtotal 1,292.02 719.71 520.70 290.05 846.28 471.41
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Figure 1 Health Care System distribution costs. 
Figure 2 Cost analysis for TRD+ and TRD- groups.
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Discussion
Results from this study are consistent with the literature 
in that TRD+ is a common condition and treatment for 
when compared to TRD- patients.19-22 Due to the nature of 
the psychiatric institution in which these data were col-
lected (i.e., a tertiary center), the high prevalence of TRD+ 
suboptimal doses of medication. It has been reported that, 
for reasons that are not fully understood, patients seen in 
academic institutions often receive suboptimal medica-
tion doses.15  
in tertiary care settings. Studies conducted in managed 
care settings13,27 suggest that only 11% of patients in need 
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the list payment values of the Brazilian Medical Association 
current hospital costs. In contrast, because medication is 
listed according to the market price, its cost is more likely 
we were unable to account for the costs of non-medical 
staff or certain procedures (e.g., social worker care, staff 
meetings to discuss treatment, use of disposable material) 
may have contributed to an increase in the medication costs 
in this study.
Certain limitations should be considered in interpreting 
• 
a tertiary care hospital that is likely not representa-
tive of public mental healthcare services in Brazil. 
Furthermore, being a teaching hospital, multiple 
medical residents were likely responsible for patient 
care over the time encompassed by this study. This 
fact is of critical importance because this turnover 
-
tient’s history; it may be that changes in medication 
are sometimes not totally necessary. It is possible, 
in this case, that this TRD+ group could include patients 
teaching hospitals.15
•  The sample size calculation estimated that 240 patients 
of 212 patients. However, because we had a higher pro-
versus 15%), we do not believe that this fact had a sig-
sample size did not allow us to detect differences with 
regard to some variables such as resource utilization 
in other clinics and the emergency department. 
•  As all antidepressant switches and up-titrations were 
-
less of the adequacy of antidepressant dosage and 
treatment duration, the proportion of TRD+ was likely 
overestimated. 
•  Due to its retrospective nature, we were unable to 
capture indirect costs in this study. The results of “cost 
of illness” studies in depression are variable, but indi-
rect costs always account for the greater share of the 
total cost.8-11 It has also been reported that TRD+ pa-
patients.19-20
TRD+ compared to TRD- were not as substantial in our 
study as has been reported elsewhere, where TRD+ was 
reported to cost up to 6-times more than TRD-.29,32,38 
Conclusion
We assessed the costs of MDD in a tertiary reference hospital. 
should be considered by policy makers when implementing 
public mental health initiatives. Despite inherent limita-
TRD+, is associated with high treatment costs. Considering 
that indirect costs were not captured in this study, we urge 
future studies to account for these costs to further measure 
the economic impact of depression on the healthcare system. 
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of antidepressant therapies receive the proper dose and 
duration of treatment. This issue may have contributed to 
our study used an algorithm to categorize patients into the 
TRD+ or TRD- groups based on medication records rather 
than actual face-to-face psychiatric assessment. Groups were 
similar regarding sociodemographic characteristics, as well 
as psychiatric and non-psychiatric comorbidities. Clinical 
factors found to be associated with treatment resistance in 
28 were 
to the small sample size. 
Individuals with TRD+ utilize more resources and are 
substantially more costly to the health system compared to 
previous use of resources that results in an increased use of 
resources. Medication costs were responsible for 70% of the 
total costs in our sample, whereas the per diem hospitaliza-
When comparing the two groups, we found no differences 
regarding the number of medical visits or laboratory tests 
differences in the treatment for disorders other than MDD. 
an increased severity of depression translates into higher 
health-care utilization and costs for comorbid conditions18,28 
and that the improvement in the symptoms of depression is 
associated with lower resource utilization for non-depression-
related reasons.29-32 
Indeed, in our data, the costs of comorbidities accounted 
up to 70% of the costs of managing depression were due to 
the treatment of comorbidities.34 This discrepancy may be 
care often have the treatment of their comorbidities taken 
care of at the primary or secondary level. Because these 
treatments occur outside of the teaching hospital setting, 
our study did not capture these costs. 
The mean annual cost for the symptoms of depression was 
R$ 4,092.55 (US$ 2,279.72), which is greater than the costs 
of other chronic disorders in Brazil (reference). The annual 
costs of osteoporosis (2001) were R$ 748.81 per patient.35 
For schizophrenia (1998), they were R$ 1,256.00.36 
contrast with that observed in other studies that report that 
6% to 29% is associated with drug costs.10,11 In other studies, 
the most relevant cost drivers of direct costs are usually 
hospitalization (average 42% versus 21% in our study) or out-
patient care.10,11,33 This lower hospitalization cost, compared 
with the literature, is not due to lower hospitalization rates 
or shorter lengths of stay. In our study, the average number 
of annual inpatient days was similar to those found in US 
studies using claim databases for TRD+ and TRD- patients19,20 
and higher than that observed in primary care patients with 
depression in Porto Alegre, Brazil.37 The length of stay of hos-
pitalized patients was similar (42.8 days in the MDD sample) 
when compared to the average length of stay in Brazilian 
psychiatric hospitals (40 days, source: MS/SAS/DECAS/
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